CD74 a Potential Therapeutic Target for Breast Cancer Therapy: Interferon Gamma Up-regulates its Expression in CAMA-1 and MDA-MB-231 Cancer Cells

Alabdulmon, Waleed; Alhomaidan, Homaidan T.; Rasheed, Zafar; Madar, Inamul Hasan; Alasmael, Noura; Alkhatib, Shaza; Ssadh, Hussain Al

doi:10.3923/ijcr.2018.58.69

Cited by 6 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, we quantified colocalization of CD74 and CD44 in breast cancer cells through noninvasive and validated bioimaging procedure [28] and also determined several novel biomarkers involved in the pathogenesis of breast cancer [29]. Not only have these, but we also showed that treatment of human breast cancer cells with interferon-γ up-regulates the expression of CD74 along with MIF and CD44 [2], [30]. In continuation of these studies, the present study was hypothesised to find out the potential roles of CD74 in the proliferative and apoptotic activity in breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Knockdown of CD-74 in the Proliferative and Apoptotic Activity of Breast Cancer Cells

Ssadh¹,

Abdulmonem²,

Rasheed³

et al. 2019

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

BACKGROUND: The cluster of differentiation (CD) 74 is known for its immunological functions and its elevated level was reported in various cancer cells. AIM: The aim of the present study was to investigate the expression and potential roles of CD74 in the proliferative and apoptotic activity of breast cancer. METHODS: Expression of CD74, macrophage migration inhibitory factor (MIF) and CD44 was assayed in CAMA-1 and MDA-MB-231 cell lines using flow cytometry. CD74 was knocked down using CD74 siRNA-transfection in CAMA-1, and MDA-MB-231 cells and proliferation and apoptosis were determined in the transfected breast cancer cells. RESULTS: The data showed that CD74, MIF and CD44 were expressed in breast cancer cell lines and were associated with cell proliferation and apoptosis. Correlation analysis revealed that CD74 was positively correlated and colocalised with MIF on the cell-surface of CAMA-1 and MDA-MB-231. The knockdown of CD74 significantly reduced CAMA-1 and MDA-MB-231 cell proliferation and increased the level of apoptotic cells. CONCLUSION: We concluded that the interactions of CD74 with MIF and CD74 with CD44 could be a potential tumour marker for breast cancer cells. Moreover, the level of co-expression of MIF and CD74 or CD44 could be a surrogate marker for the efficacy of anti-angiogenic drugs, particularly in breast cancer tumours. In short, the study revealed the potential roles of CD74 in the proliferation and apoptosis of breast cancer which may serve as a potential therapeutic target for breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Knockdown of CD-74 in the Proliferative and Apoptotic Activity of Breast Cancer Cells

Ssadh¹,

Abdulmonem²,

Rasheed³

et al. 2019

Open Access Maced J Med Sci

Self Cite

View full text Add to dashboard Cite

show abstract

“…We validated the specificity of UMAb231 for IHC using the human breast cancer cell line MDA-MB-231. This cell line has a robust endogenous expression of CD74 protein, which can be easily upregulated with IFNγ or suppressed with siRNA [ 35 , 39 , 56 ]. Western blot analysis of whole cells extracts with endogenous expression (control lanes; Figure 1 A), siRNA-mediated depletion- (+CD74 siRNA lanes; Figure 1 A) or IFNγ-mediated up-regulation (+IFNγ lanes; Figure 1 A) of CD74, showed that the LN-2 antibody recognized a major band at 35 kDa, congruent with the expected molecular weight for CD74.…”

Section: Resultsmentioning

confidence: 99%

HLA Class II Histocompatibility Antigen γ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer

Noer

Talman

Moreira

2021

Cancers

View full text Add to dashboard Cite

The triple-negative breast cancer (TNBC) subtype, defined as negative for ER, PgR, and HER2, is biologically more aggressive and with a poorer prognosis than the other subtypes, in part due to the lack of suitable targeted therapies. Consequently, identification of any potential novel therapeutic option, predictive and/or prognostic biomarker, or any other relevant information that may impact the clinical management of this group of patients is valuable. The HLA class II histocompatibility antigen γ chain, or cluster of differentiation 74 (CD74), has been associated with TNBCs, and poorer survival. However, discordant results have been reported for immunohistochemical studies of CD74 expression in breast cancer. Here we report validation studies for use of a novel CD74 antibody, UMAb231. We used this antibody to stain a TMA including 640 human breast cancer samples, and found no association with the TNBC subtype, but did find a positive correlation with outcome. We also found associations between CD74 expression and immune cell infiltration, and expression of programmed death ligand 1 (PD-L1). Given that CD74 may play a role in innate immune system responses and the potential of immunotherapy as a viable treatment strategy for TNBCs, CD74 expression may have predictive value for immune checkpoint therapies.

show abstract

“…Bones were also collected from the experimental rat's groups and the acquired bone marrow was harvested to isolate and culture MSCs for osteoblastic differentiation. MSCs (passage 3) were tested for viability by trypan blue stain and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), (Sigma-Aldrich, USA) assays before culturing in osteogenic media as described previously (Alabdulmonem et al, 2018;Rasheed et al, 2010). The cell suspension was done at an appropriate concentration of 1 × 10 5 /ml in α-MEM as described previously (Quan et al, 2016).…”

Section: Stem Cell Samplingmentioning

confidence: 99%

Therapeutic approach for osteoporotic animal model by bone marrow mesenchymal stem cells

Aljohani¹,

Zaki²,

Waleed³

et al. 2022

J App Pharm Sci

View full text Add to dashboard Cite

Osteoporosis (OP) is a common debilitating metabolic bone disorder manifested by poor mineral density and deteriorated skeleton. Stem cell therapies are being considered as alternative therapeutic modalities. This study determined the therapeutic potential of mesenchymal stem cell (MSC) application in osteoporotic rats. To achieve this, an OP animal model was developed through ovariectomy and glucocorticoids in rats. MSCs were isolated from the same breed of rats and cultured MSCs were administered to osteoporotic rats via vein injections. After 4 and 8 weeks of MSCs administration, rats were sacrificed and all desired components, including serum and joints, were isolated. The present findings showed that the transplantation of MSCs into osteoporotic rats enhanced osteoblastic differentiation and function reverting OP. Calcium deposition, bone-specific alkaline phosphatase activity, and serum osteocalcin concentration were significantly elevated in MSCs-treated osteoporotic rats (p < 0.05). Notably, their levels were much higher in osteoporotic rats treated for 8 weeks than in those treated for 4 weeks (p < 0.05). Moreover, the histological image of the femur head showed uniform thinning of trabeculae (TB) in osteoporotic rats, resulting in the widening of intertrabecular spaces and disjointed bony ossicles interrupted by virtue of expanded fatty bone marrow spaces. Interestingly, after MSCs treatment, cancellous bone TB appeared normal with red bone marrow. Furthermore, a photomicrograph of osteogenic differentiation of MSCs of MSCs-treated osteoporotic rats showed significantly high scattered red calcified nodules (p < 0.05). In conclusion, this study illustrates that the transplantation of MSCs into osteoporotic rats provides a supplement for bone architecture and enhances osteoblastic differentiation and function, thus reverting OP. This work presents a unique method as a future application for the treatment of human OP.

show abstract

CD74 a Potential Therapeutic Target for Breast Cancer Therapy: Interferon Gamma Up-regulates its Expression in CAMA-1 and MDA-MB-231 Cancer Cells

Cited by 6 publications

References 29 publications

Knockdown of CD-74 in the Proliferative and Apoptotic Activity of Breast Cancer Cells

Knockdown of CD-74 in the Proliferative and Apoptotic Activity of Breast Cancer Cells

HLA Class II Histocompatibility Antigen γ Chain (CD74) Expression Is Associated with Immune Cell Infiltration and Favorable Outcome in Breast Cancer

Therapeutic approach for osteoporotic animal model by bone marrow mesenchymal stem cells

Contact Info

Product

Resources

About